样式: 排序: IF: - GO 导出 标记为已读
-
Tackling sorbitol intolerance Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-25 Maria Papatriantafyllou
Sorbitol, a poorly absorbable sweetener, is catabolized by gut microbiota, mainly Clostridia. Lee et al. now elucidate the pathophysiology of sorbitol intolerance and highlight a role for Clostridia and butyrate, a short-chain fatty acid metabolite. Stable engraftment of Escherichia coli strain Nissle 1917, a probiotic that catabolizes sorbitol, restored caecal SDH activity in mice and protected them
-
Seladelpar in primary biliary cholangitis Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-22 Eleni Kotsiliti
In a phase III, double-blind, placebo-controlled trial, 193 patients with primary biliary cholangitis and an inadequate response to or a history of unacceptable side effects with ursodeoxycholic acid were randomly assigned in a 2:1 ratio to receive daily 10 mg oral seladelpar (a PPARδ agonist) or placebo. The primary endpoint was set at month 12 as a biochemical response defined as an alkaline phosphatase
-
HCC genomic landscape in Chinese individuals Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-22 Eleni Kotsiliti
Researchers from the Chinese Liver Cancer Atlas project performed deep whole-genome sequencing of hepatocellular carcinoma (HCC) tumours from 494 Chinese individuals (86.4% men and 13.6% women) who received no preoperative anti-cancer treatment. According to epidemiological data, 94.5% of the enrolled patients had hepatitis B, 2.6% had hepatitis C, 26.7% drank alcohol and 36.8% smoked. The researchers
-
Bacteriophages and host inflammation in IBD Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-22 Eleni Kotsiliti
Researchers analysed metagenomic data from 1,618 patients with inflammatory bowel disease (IBD) and 791 healthy individuals as controls and identified invertible DNA orientations in Bacteroidales genomes. Of those 311 invertible regions, 147 were markedly different in terms of orientation in patients with IBD. The inverted regions included, among others, the anti-inflammatory PSA promoter of Bacteroides
-
Biomarker shows no clinical use in guiding treatment for Crohn’s disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-22 Eleni Kotsiliti
Between 29 December 2017 and 5 January 2022, in a multicentre, open-label, biomarker-stratified, interventional clinical trial (PROFILE), 386 adult patients with newly diagnosed active Crohn’s disease were randomly assigned to two groups: top-down (early combined immunosuppression with infliximab (a TNF monoclonal antibody) and an immunomodulator) or accelerated step-up (conventional) treatment. The
-
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-18 Yasser Fouad, Salma Barakat, Almoutaz Hashim, Hasmik Ghazinyan
Fatty liver disease is one of the most common liver diseases in the Middle East and North Africa region, and globally. Unfortunately, there is a lack of awareness regarding this condition. The nomenclature changes for NAFLD (to MAFLD or MASLD) have gained considerable attention in the hepatology community. Here, we present our point of view on this ongoing change and debate.
-
Future direction of total neoadjuvant therapy for locally advanced rectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-14 Yoshinori Kagawa, J. Joshua Smith, Emmanouil Fokas, Jun Watanabe, Andrea Cercek, Florian R. Greten, Hideaki Bando, Qian Shi, Julio Garcia-Aguilar, Paul B. Romesser, Natally Horvat, Hanna Sanoff, William Hall, Takeshi Kato, Claus Rödel, Arvind Dasari, Takayuki Yoshino
-
Cell senescence in liver diseases: pathological mechanism and theranostic opportunity Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-14 David Sanfeliu-Redondo, Albert Gibert-Ramos, Jordi Gracia-Sancho
-
ECCO’24 Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-13 Katrina Ray
In February 2024, Nature Reviews Gastroenterology & Hepatology attended the 19th Congress of ECCO (ECCO’24) in Stockholm, Sweden. The meeting, according to the organizers, had >7,200 participants (represented by 99 countries) and focused on inflammatory bowel disease (IBD), with this year’s congress theme being ‘Crossing Borders in IBD’. The ‘crossing borders’ theme tied well with the new REACH strategy
-
Screening for liver fibrosis: lessons from colorectal and lung cancer screening Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-13 Maja Thiele, Patrick S. Kamath, Isabel Graupera, Antoni Castells, Harry J. de Koning, Miquel Serra-Burriel, Frank Lammert, Pere Ginès
-
Group 3 innate lymphoid cells in intestinal health and disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-11 Veronika Horn, Gregory F. Sonnenberg
-
2023 FDA approvals in gastroenterology and hepatology Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-07 Eleni Kotsiliti
In 2023, the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA) approved 55 novel drugs, 4 related to gastroenterology and hepatology. In 2022, the new drug approvals included treatments for Helicobacter pylori infection, T2DM blood sugar control in addition to diet and exercise, FGFR2-aberrant intrahepatic cholangiocarcinoma and unresectable hepatocellular
-
Ultra-processed foods and food additives in gut health and disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-22 Kevin Whelan, Aaron S. Bancil, James O. Lindsay, Benoit Chassaing
-
Another renaissance for bile acid gastrointestinal microbiology Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-21 Jason M. Ridlon, H. Rex Gaskins
-
Resmetirom proves positive for NASH with liver fibrosis Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-15 Katrina Ray
Positive phase III results have been reported for resmetirom (a thyroid hormone receptor β-selective agonist) for the treatment of nonalcoholic steatohepatitis (NASH; also known as metabolic dysfunction-associated steatohepatitis (MASH)) with liver fibrosis. In a phase III, randomized controlled trial, 966 patients with biopsy-confirmed NASH and liver fibrosis (stage F1B, F2 or F3) were randomly assigned
-
A gut–liver axis in intestinal stem cell fitness Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-14 Katrina Ray
New research demonstrates that the gut–liver axis plays a part in calibrating intestinal stem cell (ISC) expansion during intestinal homeostasis in mice, with a key role for the hepatokine pigment epithelium-derived factor (PEDF). In a series of experiments using transcriptomics, proteomics and hepatectomy in mouse models, the researchers identified PEDF, a liver-derived soluble WNT inhibitor, which
-
Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-14 María R. Aburto, John F. Cryan
-
Sugemalimab with chemotherapy for advanced ESCC Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-14 Katrina Ray
A multicentre, randomized, double-blind, phase III trial reported positive results for sugemalimab (a PDL1 antibody) plus chemotherapy for the treatment of advanced oesophageal squamous cell carcinoma (ESCC). A total of 540 adults (aged 18–75 years) with unresectable, locally advanced, recurrent or metastatic ESCC who had not received prior systemic treatment were randomly assigned 2:1 to receive either
-
GLP1 agonists and risk of major adverse liver outcomes Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-14 Katrina Ray
Glucagon-like peptide 1 (GLP1) agonists could be a treatment option to reduce risk of major adverse liver outcomes (MALO) in patients with type 2 diabetes mellitus (T2DM) and any chronic liver disease (CLD) who adhere to treatment over time, according to estimates using modelling of observational data to emulate a target trial of GLP1 agonists in this population. Observational data from Swedish health-care
-
Live bacterial therapeutics for detection and treatment of colorectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-14 Joanna Zhang, Jeff Hasty, Amir Zarrinpar
-
HCV direct-acting antiviral therapy adherence in people who inject drugs Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-12 Jordan Hindson
A new study (HERO) published in the Journal of Hepatology has investigated the association between direct-acting antiviral treatment adherence and sustained virological response (SVR) in patients with hepatitis C virus (HCV) infection and who inject drugs. Over a 12-week treatment period, electronic blister packs assessed adherence to sofosbuvir with velpatasvir in people who inject drugs (n = 623
-
Linaclotide for functional constipation in paediatric patients: phase III results Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-12 Jordan Hindson
Linaclotide is a guanylate cyclase C agonist used for the treatment of chronic idiopathic constipation in adults. A randomized, multicentre phase III trial assessed use of linaclotide in paediatric patients with functional constipation. 330 patients (6–17 years of age) were randomly assigned to receive oral linaclotide (72 μg) or placebo once per day for a 12-week period. Patients in the linaclotide
-
Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-12 Jordan Hindson
A multicentre, randomized phase II trial in China assessed use of sintilimab, a PD1 inhibitor, as adjuvant therapy in patients with hepatocellular carcinoma (HCC) with microvascular invasion who had undergone curative resection. These patients are at high risk of recurrence. Patients (n = 198) were randomized to sintilimab (intravenous injections every 3 weeks for eight cycles) or active surveillance
-
Evidence-based alcohol policies are the answer Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-09 William Gilmore, Ian Gilmore
A new study by Díaz and colleagues links strong alcohol policy with improved health and societal outcomes. The evidence for what works to reduce the enormous burden from alcohol is clear. The question is why are governments still not acting?
-
Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-09 Ludvig M. Sollid
-
Connecting with the community Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-07
The Editors of Nature Reviews Gastroenterology & Hepatology travel regularly to conferences to meet with the research community and keep up to date on the latest research and key trends in the field. Come and say hello!
-
Effects of dietary fibre on metabolic health and obesity Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-07 Edward C. Deehan, Valentin Mocanu, Karen L. Madsen
-
Hepatic glucose metabolism in the steatotic liver Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-02-02 Egeria Scoditti, Silvia Sabatini, Fabrizia Carli, Amalia Gastaldelli
-
Intestinal mitochondria and dietary lipids Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-01-30 Eleni Kotsiliti
New research found that enterocyte mitochondrial dysfunction can affect intestinal lipid storage and transport. There is “a highly specific response and direct link between mitochondrial function and chylomicron production,” explains corresponding author Manolis Pasparakis.
-
A role for the gut microbiota in immune checkpoint inhibitor-induced colitis Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-01-23 Katrina Ray
New research demonstrates that colitis induced by cytotoxic T lymphocyte protein 4 (CTLA4) blockade depends on the gut microbiota, which induces activation of CD4+ T cells and depletion of regulatory T (Treg) cells via the Fcγ receptor. Importantly, anti-CTLA nanobodies that lacked the Fc domain stimulated antitumour immunity in mouse models without inducing colitis.
-
RNA modification-mediated mRNA translation regulation in liver cancer: mechanisms and clinical perspectives Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-01-19 Shuibin Lin, Ming Kuang
-
Effect of expectation of gluten intake on non-coeliac gluten sensitivity Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-01-15 Jordan Hindson
People with non-coeliac gluten sensitivity (NCGS) report gastrointestinal symptoms after gluten consumption in the absence of coeliac disease or wheat allergy. However, the mechanism by which gluten can induce gastrointestinal symptoms in individuals with NCGS is unclear. In a new study published in The Lancet Gastroenterology & Hepatology, researchers conducted a randomized, double-blind study that
-
Contrasting aspects of human excreta Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-01-12 Seung-min Park
Our Ig Nobel Prize-winning smart toilet research confronts societal taboos and uses humour as a gateway to advance serious dialogue about health technology. It is a call to action to embrace innovation, foster richer scientific discussions and support pioneering research for tangible health advancements.
-
Are all the IL-23 blockers the same in inflammatory bowel disease? Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-01-05 Silvio Danese, Laurent Peyrin-Biroulet
-
Pathophysiology of gastro-oesophageal reflux disease: implications for diagnosis and management Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-01-04 Julieta Argüero, Daniel Sifrim
-
Autism spectrum disorders and the gastrointestinal tract: insights into mechanisms and clinical relevance Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-19 Lin Y. Hung, Kara Gross Margolis
-
Neutrophils: from IBD to the gut microbiota Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-18 Camille Danne, Jurate Skerniskyte, Benoit Marteyn, Harry Sokol
-
Guidelines for best practices in monitoring established coeliac disease in adult patients Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-18 Luca Elli, Daniel Leffler, Christophe Cellier, Benjamin Lebwohl, Carolina Ciacci, Michael Schumann, Knut E. A. Lundin, Stefania Chetcuti Zammit, Reena Sidhu, Leda Roncoroni, Julio C. Bai, Anne R. Lee, Melinda Dennis, Marie E. Robert, Kamran Rostami, Sherine Khater, Isabel Comino, Angel Cebolla, Federica Branchi, Elena F. Verdu, Juan Pablo Stefanolo, Randi Wolf, Sheba Bergman-Golden, Nick Trott, Luigia
-
The maternal gut microbiome in pregnancy: implications for the developing immune system Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-14 Omry Koren, Liza Konnikova, Petter Brodin, Indira U. Mysorekar, Maria Carmen Collado
-
A new era in obesity management Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-13 Fatima Cody Stanford
-
Fermented foods and gastrointestinal health: underlying mechanisms Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-11 Arghya Mukherjee, Samuel Breselge, Eirini Dimidi, Maria L. Marco, Paul D. Cotter
-
Gut microbiota in overweight and obesity: crosstalk with adipose tissue Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-08 Patrice D. Cani, Matthias Van Hul
-
Novel interventions against alcohol-related liver disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-11 Maja Thiele, Christophe Moreno
-
Tumour-associated macrophages and pancreatic cancer: an inflammatory loop Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-07 Jordan Hindson
In a new study published in Nature, researchers have investigated the role of tumour-associated macrophages (TAMs) in pancreatic cancer. It has previously been shown that pancreatic ductal adenocarcinoma (PDAC) tumours are infiltrated by TAMs linked to pathogenic inflammation. “We were particularly interested in understanding how inflammation promotes pancreatic cancer, and what was the role of macrophages
-
RET signalling controls gut motility Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-08 Katrina Ray
RET signalling in the adult gastrointestinal epithelium has a key role in controlling gut motility by influencing enteroendocrine cell (EEC) function via peptide YY (PYY), according to new research, which also highlighted sex-dependent effects of disruption of epithelial RET signalling.
-
New options for late-line treatment of metastatic colorectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-08 Sara Lonardi, Filippo Pietrantonio
-
Upgrading therapeutic ambitions and treatment outcomes Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-07 Paulo Gustavo Kotze, Severine Vermeire
-
Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-06 Norbert Stefan, Amedeo Lonardo, Giovanni Targher
-
Microbiota-based biomarkers and therapeutics for cancer management Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-12-06 William K. K. Wu, Jun Yu
-
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-30 Thomas F. Stoop, Rutger T. Theijse, Leonard W. F. Seelen, Bas Groot Koerkamp, Casper H. J. van Eijck, Christopher L. Wolfgang, Geertjan van Tienhoven, Hjalmar C. van Santvoort, I. Quintus Molenaar, Johanna W. Wilmink, Marco Del Chiaro, Matthew H. G. Katz, Thilo Hackert, Marc G. Besselink
-
Elafibranor in primary biliary cholangitis Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-30 Eleni Kotsiliti
A new study published in The New England Journal of Medicine evaluated the efficacy and safety of elafibranor, an oral, dual PPARα and PPARδ agonist, in primary biliary cholangitis (PBC).
-
See the reality again in the field of liver transplantation Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-27 Nam-Joon Yi
In 2023, we witnessed advances in allocation policies and marginal donors, including living donors. Key improvements included the uncapped Model for End-stage Liver Disease 3.0 score, unveiled machine perfusion trials to standard deceased donors and lessons from the aborted living donor liver transplantations.
-
Resmetirom safe for nonalcoholic fatty liver disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-21 Katrina Ray
A 52-week randomized, double-blind, placebo-controlled phase III trial (MAESTRO-NAFLD-1) evaluated the safety of resmetirom in adults with nonalcoholic fatty liver disease and presumed nonalcoholic steatohepatitis. Patients were randomly assigned to either 100 mg resmetirom, 80 mg resmetirom or placebo, or open-label 100 mg resmetirom. Resmetirom was safe and well tolerated (no difference in the primary
-
Risk of HCC in individuals of sub-Saharan ethnicity or descent with chronic hepatitis B in Europe Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-21 Katrina Ray
Cross-sectional studies have indicated that individuals from sub-Saharan Africa (SSA) with chronic hepatitis B are a potential risk group for hepatocellular carcinoma (HCC). An international multicentre retrospective cohort study of individuals of SSA or Afro-Surinamese ethnicity or descent with chronic hepatitis B in the UK, Netherlands and Spain has examined the incidence of HCC in this population
-
Amitriptyline as second-line treatment for IBS in primary care settings Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-21 Katrina Ray
Titrated low-dose amitriptyline (a tricyclic antidepressant) was superior to placebo as a second-line treatment for irritable bowel syndrome (IBS) in primary care according to results from a new randomized, double-blind, placebo-controlled phase III trial (ATLANTIS). Across 55 general practices in England, 463 participants with IBS (mean age 48.5 years; 68% female, 32% male) were randomly assigned
-
Fresh perspectives on how to build, maintain and repair the ENS Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-17 Werend Boesmans
-
Deciphering the different phases of preclinical inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-10 Jonas J. Rudbaek, Manasi Agrawal, Joana Torres, Saurabh Mehandru, Jean-Frederic Colombel, Tine Jess
-
Implications of the evolving knowledge of the genetic architecture of MASLD Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-03 Luca V. C. Valenti, Vittoria Moretti
-
Folate receptor-γ in MASH-related fibrosis Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-02 Eleni Kotsiliti
A new study published in Science Translational Medicine describes the role of folate receptor-γ (FOLR3) in metabolic dysfunction-associated steatohepatitis (MASH) liver fibrogenesis. “Our research suggests further exploration of FOLR3 as a promising biomarker and potential target for therapeutic interventions,” explains corresponding author of the study Salim Merali.
-
Innovation is needed to increase viral hepatitis testing globally Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-11-02 Margaret E. Hellard, Alisa Pedrana